Loading organizations...
§ Private Profile · Sunnyvale, CA, USA
A private biopharmaceutical company developing a novel transdermal treprostinil prodrug patch for pulmonary arterial hypertension (PAH).
Corsair Pharma is a Sunnyvale, California-based biopharmaceutical company developing a once-daily transdermal patch utilizing a novel prodrug of treprostinil to treat pulmonary arterial hypertension. The venture-backed enterprise aims to provide consistent drug levels and reduce side effects for a target market of approximately 45,000 patients currently undergoing treatment in the United States. The private entity has financed its ongoing clinical development pipeline through institutional venture capital investments, including a completed Series B funding round. The executive leadership team features industry veterans such as Chief Executive Officer George W. Mahaffey, who previously managed the launch of the therapeutic drug Ventavis, alongside President Bobby Singh. The corporate board of directors is chaired by Ivan Gergel, a managing partner at the healthcare investment firm New Rhein Healthcare. Corsair Pharma was officially established in 2014 by an undisclosed group of founders.
Corsair Pharma has raised $23.0M across 1 funding round.
Corsair Pharma has raised $23.0M in total across 1 funding round.
Corsair Pharma has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series B in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $23M Series B | NEW Rhein Healthcare Investors | Junson Capital, Midas Capital, Plaisance Capital Management, Primavera Capital Group | Announced |
Corsair Pharma has raised $23.0M in total across 1 funding round.
Corsair Pharma's investors include New Rhein Healthcare Investors, Junson Capital, Midas Capital, Plaisance Capital Management, Primavera Capital Group.
Corsair Pharma is a biopharmaceutical company focused on developing innovative therapeutics for pulmonary arterial hypertension (PAH). Its lead product candidate is a proprietary transdermal patch delivering a prodrug of treprostinil, designed to provide safer, more convenient, and better-tolerated treatment compared to existing therapies. The patch aims to maintain consistent drug levels without the need for infusion pumps or central venous catheters, addressing key challenges such as infusion site pain and reactions. Corsair Pharma serves patients with PAH and potentially other forms of pulmonary hypertension, advancing toward Phase 1 clinical trials with strong growth momentum supported by strategic partnerships, including one with United Therapeutics, a leader in PAH therapies[1][2][5].
Corsair Pharma was founded by a team with expertise in biopharmaceutical development, motivated by the need to improve the therapeutic profile and patient experience of PAH treatments. The idea emerged from recognizing the limitations of current infusion-based therapies and leveraging prodrug and transdermal delivery technologies to create a novel solution. Early traction includes successful completion of preclinical programs and the appointment of experienced leadership, such as CEO George W. Mahaffey, positioning the company for clinical advancement and commercial success[2][6].
Corsair Pharma is riding the trend toward patient-centric, non-invasive drug delivery systems that improve adherence and quality of life for chronic disease patients. The timing is favorable due to growing demand for better PAH treatments and advances in prodrug and transdermal technologies. Market forces such as the limitations of current infusion therapies and the need for safer, more convenient options support Corsair’s approach. By pioneering a novel delivery platform, Corsair influences the pulmonary hypertension treatment ecosystem and potentially broader therapeutic areas requiring improved drug administration methods[1][2].
Corsair Pharma is poised to advance into clinical trials and potentially transform PAH treatment paradigms with its transdermal prodrug patch. Future trends shaping its journey include increasing emphasis on patient-friendly therapies, regulatory support for innovative delivery technologies, and expanding indications for pulmonary hypertension. As the company progresses, its influence may grow beyond PAH, setting new standards for drug delivery and patient care in chronic diseases. Corsair’s commitment to quality, strategic partnerships, and innovative science positions it well for sustained impact in biopharma[2][3][6].